Global Dendritic Cell Cancer Vaccine Market is valued at approximately USD 236.6 million in 2021 and is anticipated to grow with a healthy growth rate of more than 12.18% over the forecast period 2022-2029. Dendritic cells (DCs) are an uncommon class of leukocytes. Due to their exceptional effectiveness in presenting antigens to T cells, they have recently been applied to therapeutic cancer vaccinations. Experimental animals are found to develop both preventive and curative anti-tumor immunity after receiving isolated DCs that have been ex vivo loaded with tumor antigens and delivered as a cellular vaccine. The market is expanding because of significant factors such as the rise in the demand for cancer vaccines and increasing healthcare expenditure as well as research.t.

According to the GLOBOCAN 2020 report, which was released by the International Agency for Research on Cancer and estimated the incidence and mortality of 36 cancers in 185 countries worldwide, there were reportedly 19,292,789 new cases of cancer diagnosed in 2020 and roughly 9,958,133 cancer-related deaths worldwide. Males made up 10,065,305 of the total diagnosed cases of cancer, while females made up 9,227,484 of those cases. By 2040, it was predicted that there will be 15,585,096 cases of cancer in men and 13,302,846 in women. The prevalence of cancer in the world’s population is anticipated to fuel market expansion. Additionally, in November 2020, Moderna Inc. reported interim data from the expansion cohort of its ongoing Phase 1 research using Merck’s Keytruda and its mRNA personalized cancer vaccine (PCV), mRNA-4157. The findings showed that the vaccine candidate is well tolerated at all dose levels and produced responses as indicated by tumour shrinkage in HPV-negative head and neck squamous cell carcinoma (HNSCC) patients. However, potential Side Effects Caused by Cancer Vaccines and Low accessibility to vaccines in remote areas stifle market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Dendritic Cell Cancer Vaccine Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the market share globally owing to the rise in the incidence of cancer cases and extensive research studies sponsored by academic research institutes and pharmaceutical giants. On the other side, Europe is expected to be the fastest growing region due to the rising incidence of cancer, the rise in support for research studies from cancer societies across Europe, and emerging market players in the region positively impacting the growth of the dendritic cell cancer vaccine market.

Major market player included in this report are:
ImmunoCellular Therapeutics Ltd
GlaxoSmithKline plc,
3M Company
Activartis Biotech GmbH
DanDrit Biotech A/S
Batavia Bioservices
Argos Therapeutics
Sanpower Group
Elios Therapeutics
DCPrime

Recent Developments in the Market:
? Medigene and BioNTech have partnered to collaborate on the development of T-cell immunotherapies that target several solid tumour sites. Under the partnership, Medigene’s preclinical T-cell receptors (TCR) initiatives, which employ Medigene’s switch-receptor technology for the creation of TCR treatments and dendritic cell vaccines, will be acquired by BioNTech.

Global Dendritic Cell Cancer Vaccine Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product Outlook, End Use Outlook, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Outlook:
CreaVax
Sipuleucel-T (Provenge)
Other
By End Use Outlook:
Pediatrics
Adults

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World